Gilead Sciences (GILD) said Friday that its experimental drug, trodelvy, met the primary endpoint in a phase 3 trial, showing a statistically significant and clinically meaningful improvement in progression-free survival over chemotherapy in patients with a type of breast cancer who are not candidates for immunotherapy.
The company said the drug's safety profile in the study was consistent with previous trials, with no new safety signals observed.
The drugmaker said overall survival, a key secondary endpoint, was not yet mature at the time of analysis, and further monitoring is underway.
Gilead said it is also evaluating trodelvy in multiple ongoing phase 3 studies across various tumor types, including HER2-negative breast cancer, lung, and gynecologic cancers.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。